Efficacy and limitations of systemic corticosteroids in patients with CRSwNP compared to alternative therapies with monoclonal antibodies: real-life of 101 patients from the Lazio region, Italy

Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) is a chronic inflammatory disease. Its severe uncontrolled form may share, with asthma and atopic dermatitis, the pathophysiological mechanism of T helper 2 inflammation, characterized by tissue eosinophilia and high local IgE levels. Comorbidities a...

Full description

Saved in:
Bibliographic Details
Main Authors: F. Anastasi, C. Di Nota, S. Sessi, A. Marzetti, A. Sambito, M. Della Casa, S. Pizzolante, G. Bandiera
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-06-01
Series:Frontiers in Allergy
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/falgy.2025.1573764/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849694113770766336
author F. Anastasi
F. Anastasi
C. Di Nota
S. Sessi
A. Marzetti
A. Sambito
M. Della Casa
S. Pizzolante
G. Bandiera
author_facet F. Anastasi
F. Anastasi
C. Di Nota
S. Sessi
A. Marzetti
A. Sambito
M. Della Casa
S. Pizzolante
G. Bandiera
author_sort F. Anastasi
collection DOAJ
description Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) is a chronic inflammatory disease. Its severe uncontrolled form may share, with asthma and atopic dermatitis, the pathophysiological mechanism of T helper 2 inflammation, characterized by tissue eosinophilia and high local IgE levels. Comorbidities and the severity of symptoms result in a poor quality of life. CRSwNP is difficult to treat both medically and surgically. Systemic corticosteroids are widely used to manage signs and symptoms of this disease. However, prolonged use of systemic corticosteroids is associated with numerous side effects that limit their long-term use. Alternative therapy with new biologic drugs allows good control of the signs and symptoms of CRSwNP, without the side effects of systemic corticosteroids. Through an interview proposed to patients affected by CRSwNP, the use of systemic corticosteroids, their dosage and the methods of administration were analyzed in the period preceding the start of therapy with biological drugs and the real impact of biological therapy on corticosteroid use.
format Article
id doaj-art-2357dbb879f74462b560f6aaada44b47
institution DOAJ
issn 2673-6101
language English
publishDate 2025-06-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Allergy
spelling doaj-art-2357dbb879f74462b560f6aaada44b472025-08-20T03:20:12ZengFrontiers Media S.A.Frontiers in Allergy2673-61012025-06-01610.3389/falgy.2025.15737641573764Efficacy and limitations of systemic corticosteroids in patients with CRSwNP compared to alternative therapies with monoclonal antibodies: real-life of 101 patients from the Lazio region, ItalyF. Anastasi0F. Anastasi1C. Di Nota2S. Sessi3A. Marzetti4A. Sambito5M. Della Casa6S. Pizzolante7G. Bandiera8Unit of Otorhinolaryngology, Medical and Surgical Rhinology, Ospedale San Giovanni Evangelista, Tivoli, ItalyDepartment Faculty of Medicine, Unicamillus—Saint Camillus International University of Health and Medical Sciences, Rome, ItalyUnit of Otorhinolaryngology and Maxillofacial Surgery, Ospedale F. Spaziani- Frosinone, Frosinone, ItalyUnit of Otorhinolaryngology and Maxillofacial Surgery, Ospedale F. Spaziani- Frosinone, Frosinone, ItalyUnit of Otorhinolaryngology and Maxillofacial Surgery, Ospedale F. Spaziani- Frosinone, Frosinone, ItalyUnit of Otorhinolaryngology, Ospedale Belcolle ASL Viterbo, Viterbo, ItalyUnit of Otorhinolaryngology, Ospedale Belcolle ASL Viterbo, Viterbo, ItalyOtolaryngology Unit, Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), Faculty of Medicine and Psychology, Sapienza University, Rome, ItalyOtolaryngology Unit, Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), Faculty of Medicine and Psychology, Sapienza University, Rome, ItalyChronic Rhinosinusitis with Nasal Polyps (CRSwNP) is a chronic inflammatory disease. Its severe uncontrolled form may share, with asthma and atopic dermatitis, the pathophysiological mechanism of T helper 2 inflammation, characterized by tissue eosinophilia and high local IgE levels. Comorbidities and the severity of symptoms result in a poor quality of life. CRSwNP is difficult to treat both medically and surgically. Systemic corticosteroids are widely used to manage signs and symptoms of this disease. However, prolonged use of systemic corticosteroids is associated with numerous side effects that limit their long-term use. Alternative therapy with new biologic drugs allows good control of the signs and symptoms of CRSwNP, without the side effects of systemic corticosteroids. Through an interview proposed to patients affected by CRSwNP, the use of systemic corticosteroids, their dosage and the methods of administration were analyzed in the period preceding the start of therapy with biological drugs and the real impact of biological therapy on corticosteroid use.https://www.frontiersin.org/articles/10.3389/falgy.2025.1573764/fullCRSwNPTh2 inflammationsystemic corticosteroidpharmaco economicbiological therapyasthma
spellingShingle F. Anastasi
F. Anastasi
C. Di Nota
S. Sessi
A. Marzetti
A. Sambito
M. Della Casa
S. Pizzolante
G. Bandiera
Efficacy and limitations of systemic corticosteroids in patients with CRSwNP compared to alternative therapies with monoclonal antibodies: real-life of 101 patients from the Lazio region, Italy
Frontiers in Allergy
CRSwNP
Th2 inflammation
systemic corticosteroid
pharmaco economic
biological therapy
asthma
title Efficacy and limitations of systemic corticosteroids in patients with CRSwNP compared to alternative therapies with monoclonal antibodies: real-life of 101 patients from the Lazio region, Italy
title_full Efficacy and limitations of systemic corticosteroids in patients with CRSwNP compared to alternative therapies with monoclonal antibodies: real-life of 101 patients from the Lazio region, Italy
title_fullStr Efficacy and limitations of systemic corticosteroids in patients with CRSwNP compared to alternative therapies with monoclonal antibodies: real-life of 101 patients from the Lazio region, Italy
title_full_unstemmed Efficacy and limitations of systemic corticosteroids in patients with CRSwNP compared to alternative therapies with monoclonal antibodies: real-life of 101 patients from the Lazio region, Italy
title_short Efficacy and limitations of systemic corticosteroids in patients with CRSwNP compared to alternative therapies with monoclonal antibodies: real-life of 101 patients from the Lazio region, Italy
title_sort efficacy and limitations of systemic corticosteroids in patients with crswnp compared to alternative therapies with monoclonal antibodies real life of 101 patients from the lazio region italy
topic CRSwNP
Th2 inflammation
systemic corticosteroid
pharmaco economic
biological therapy
asthma
url https://www.frontiersin.org/articles/10.3389/falgy.2025.1573764/full
work_keys_str_mv AT fanastasi efficacyandlimitationsofsystemiccorticosteroidsinpatientswithcrswnpcomparedtoalternativetherapieswithmonoclonalantibodiesreallifeof101patientsfromthelazioregionitaly
AT fanastasi efficacyandlimitationsofsystemiccorticosteroidsinpatientswithcrswnpcomparedtoalternativetherapieswithmonoclonalantibodiesreallifeof101patientsfromthelazioregionitaly
AT cdinota efficacyandlimitationsofsystemiccorticosteroidsinpatientswithcrswnpcomparedtoalternativetherapieswithmonoclonalantibodiesreallifeof101patientsfromthelazioregionitaly
AT ssessi efficacyandlimitationsofsystemiccorticosteroidsinpatientswithcrswnpcomparedtoalternativetherapieswithmonoclonalantibodiesreallifeof101patientsfromthelazioregionitaly
AT amarzetti efficacyandlimitationsofsystemiccorticosteroidsinpatientswithcrswnpcomparedtoalternativetherapieswithmonoclonalantibodiesreallifeof101patientsfromthelazioregionitaly
AT asambito efficacyandlimitationsofsystemiccorticosteroidsinpatientswithcrswnpcomparedtoalternativetherapieswithmonoclonalantibodiesreallifeof101patientsfromthelazioregionitaly
AT mdellacasa efficacyandlimitationsofsystemiccorticosteroidsinpatientswithcrswnpcomparedtoalternativetherapieswithmonoclonalantibodiesreallifeof101patientsfromthelazioregionitaly
AT spizzolante efficacyandlimitationsofsystemiccorticosteroidsinpatientswithcrswnpcomparedtoalternativetherapieswithmonoclonalantibodiesreallifeof101patientsfromthelazioregionitaly
AT gbandiera efficacyandlimitationsofsystemiccorticosteroidsinpatientswithcrswnpcomparedtoalternativetherapieswithmonoclonalantibodiesreallifeof101patientsfromthelazioregionitaly